Distant metastasis of alveolar rhabdomyosarcoma with pancreatic parameningeal localization in children: clinical case series

Rhabdomyosarcoma is a malignant neoplasm that develops from embryonic mesenchymal cells, with an annual incidence of 4.3 cases per 1,000,000 children. The prevalence of the tumor process is estimated on the basis of data from a comprehensive examination, including magnetic resonance imaging with intravenous contrast, ultrasound examination of the primary focus of regional and distant metastasis zones, computed tomography and radioisotope studies. The overall 5-year survival rate for localized rhabdomyosarcoma reaches 70 %. During the initial diagnosis, distant metastasis to the lungs, bones, and bone marrow is detected, which significantly worsens the prognosis in 20–25 % of patients. The factors of an extremely unfavorable prognosis for the course of alveolar rhabdomyosarcoma are the occurrence of regional and distant metastases before the start of specific treatment, dissemination of the tumor lesion during treatment, and the presence of translocation of the 13q14 sector. Publications contain data on a high (11.2 %) prevalence of metastases of alveolar rhabdomyosarcoma in the pancreas. In the presence of metastatic lesions of the pancreas, surgical treatment is effective only in combination with chemoradiotherapy. Long-term results of treatment of this cohort of children are unsatisfactory due to the high risk of recurrence and dissemination of the tumor.

Aim. To study risk factors, evaluate methods and prospects for the treatment of children with metastatic pancreatic lesions in parameningeal alveolar rhabdomyosarcoma. The article considers three clinical cases of such a lesion. We would like to draw the attention of pediatric oncologists and radiologists to the possible association of metastases in the pancreas in children with localization of rhabdomyosarcoma in the head and neck region, which requires improvement of examination protocols in this group of patients.

1. Sultan I., Qaddoumi I., Yaser S. et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2, 600 patients. J Clin Oncol 2009;27(20):3391–7. DOI: 10.1200/JCO.2008.19.7483

2. Ognjanovic S., Linabery A.M., Charbonneau B. et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer 2009;115(18):4218–26. DOI: 10.1002/cncr.24465

3. Pappo A.S., Shapiro D.N., Crist W.M. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 1997;44(4):953–72. DOI: 10.1016/S0031-3955(05)70539-3

4. Sharlai A.S., Botiralieva G.K., Druy A.E. et al. Prevalence of FOXO1 gene abnormalities in a group of round-cell rhabdomyosarcomas with alveolar morphology. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2020;19(4):82–7. (In Russ.) DOI: 10.24287/1726-1708-2020-19-4-82-87

5. Thway K., Wang J., Wren D. et al. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma. Virchows Arch 2015;467(2):217–24. DOI: 10.1007/s00428-015-1777-9

6. Rudzinski E.R., Anderson J.R., Chi Y.Y. et al. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2017;64(12):10.1002/pbc.26645. DOI: 10.1002/pbc.26645

7. Dagher R., Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999;4:34–44.

8. Enzinger F.M., Shiraki M. Alveolar rhabdomyosarcoma. An analysis of 110 cases. Cancer 1969;24(1):18–31. DOI: 10.1002/1097-0142(196907)24:1<18:AID-CNCR2820240103>3.0.CO;2-5

9. Maurer H.M., Gehan E.A., Beltangady M. et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71(5):1904–22. DOI: 10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x

10. Crist W., Gehan E.A., Ragab A.H. et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13(3):610–30. DOI: 10.1200/JCO.1995.13.3.610

11. Jha P., Frölich A.M.J. Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging. Pediatr Radiol 2010;40(8):1380–6. DOI: 10.1007/s00247-010-1572-3

12. Khalbuss W.E., Gherson J., Zaman M. Pancreatic metastasis of cardiac rhabdomyosarcoma diagnosed by fine needle aspiration. A case report. Acta Cytol 1999;43(3):447–51. DOI: 10.1159/000331098

13. Scott J., Cowell J., Robertson M.E. et al. Insulin-like growth factor-II gene expression in Wilms’ tumour and embryonic tissues. Nature 1985;317(6034):260–2. DOI: 10.1038/317260a0

14. El-Badry O.M., Minniti C., Kohn E.C. et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1(7):325–31.

15. McCarville M.B., Christie R., Daw N.C. et al. PET/CT in the evaluation of childhood sarcomas. AJR 2005;184(4): 1293–304. DOI: 10.2214/ajr.184.4.01841293

16. Norman G., Fayter D., Lewis-Light K. et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open 2015;5(1):e006030. DOI: 10.1136/bmjopen-2014-006030

17. Tateishi U., Hosono A., Makimoto A. et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009;23(2):155–61. DOI: 10.1007/s12149-008-0219-z

18. Volker T., Denecke T., Steffen I. et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25(34):5435–41. DOI: 10.1200/JCO.2007.12.2473

19. Kleis M., Daldrup-Link H., Matthay K. et al. Diagnostic value of PET/ CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009;36(1):23–36. DOI: 10.1007/s00259-008-0911-1

20. Ayalon D., Glasser T., Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11(5):289–97. DOI: 10.1054/ghir.2001.0244